Wednesday, September 29, 2021 1:48:55 PM
A candidate family of blarcamesine rare diseases.
As I’ve contended before, there is a group of closely-related rare diseases for which blarcamesine is very likely to be profoundly therapeutic, even prophylactic.
As a biologist, I’ve studied these closely. I, personally, have one of the diseases.
The family of diseases are those included in HSP, hereditary spastic paraplegia (of which there are a wide diversity of genotypes and phenotypes), and primarily lateral sclerosis (PLS).
In all of these, neurons fail to function properly. Most often, neurons controlling muscles (motor neurons) become hyper-excited, firing often, strongly, or continuously. That causes the spasticity, the continuing contraction in various muscles.
Personally, I have a very mild, late-onset version of HSP—which, in fact, was not hereditary. Many cases of HSP are actually spontaneous, not genetically inherited; merely an incidental mutation. Neither of my parents had HSP, and neither of my children inherited it; thankfully. In my case, the motor neurons controlling the adductor muscles of my legs (and a few other, minor ones, especially in the bladder—now have a suprapubic catheter) are continuously taught. I can walk, with a walker; am able to drive a car very safely and effectively; but couldn’t operate a stick-shift car. Can no longer ascend stairs.
For those with more severe HSP, a rubber bladder is surgically implanted the spinal column. It exudes into the nerves controlling the legs gamma-aminobutyric acid (GABA). This is the chemical missing in the affected motor neurons. GABA is an important (well, crucial) suppressor of nerve over-activity, hyper-excitability. When deficient, nerves fire too easily, causing all sorts of end-of-nerve anomalies.
My case of HSP is not bad enough to prompt the intense surgical procedure of implanting the rubber bladder in my spinal cord, thankfully. My case does not seem to be advancing, thankfully.
Here’s where blarcamesine will come into play with probably all forms of both HSP and PLS. In virtually all cases, neurons are lacking proper, effective concentrations of GABA; hence the over-excitability of the nerves. It was noted in the early findings of blarcamesine against Rett syndrome, in the early safety/tolerability study, that levels of GABA were dramatically increased, normalized by the drug; yielding increased normalization of motor neuron function.
Many years ago, there was a small study of blarcamesine included in the drinking water of lab rats with HSP genes. Like myself, they had reduced control and function of their spastic rear legs. Then, after they drank water with some blarcamesine in it, they rather promptly (in a week or two, as I recall) regained complete motor control of their leg muscles and twirled inside the exercise wheel like normal rats. Blarcamesine (Anavex 2-73) completely obviated the GABA deficiency, allowed normal walking. A cure, dare I say.
(Two years ago, my computer hard drive crashed; I lost the copy of that report; which I believe was in France. I’ve been unable to find it on the internet. If anyone can retrieve it, please post.)
A rare disease? Yes. “The HSP incidence rate in the United States is about 20,000 people.” But for many, very tragic, in the most severe cases:
https://sp-foundation.org/understanding-pls-hsp/hsp.html
When available, I’ll be one of the first to take blarcamesine, off-label, for my HSP. Will be rather expensive, my health insurance won’t pay for it. May have to liquidate a few AVXL shares, then.
As I’ve contended before, there is a group of closely-related rare diseases for which blarcamesine is very likely to be profoundly therapeutic, even prophylactic.
As a biologist, I’ve studied these closely. I, personally, have one of the diseases.
The family of diseases are those included in HSP, hereditary spastic paraplegia (of which there are a wide diversity of genotypes and phenotypes), and primarily lateral sclerosis (PLS).
In all of these, neurons fail to function properly. Most often, neurons controlling muscles (motor neurons) become hyper-excited, firing often, strongly, or continuously. That causes the spasticity, the continuing contraction in various muscles.
Personally, I have a very mild, late-onset version of HSP—which, in fact, was not hereditary. Many cases of HSP are actually spontaneous, not genetically inherited; merely an incidental mutation. Neither of my parents had HSP, and neither of my children inherited it; thankfully. In my case, the motor neurons controlling the adductor muscles of my legs (and a few other, minor ones, especially in the bladder—now have a suprapubic catheter) are continuously taught. I can walk, with a walker; am able to drive a car very safely and effectively; but couldn’t operate a stick-shift car. Can no longer ascend stairs.
For those with more severe HSP, a rubber bladder is surgically implanted the spinal column. It exudes into the nerves controlling the legs gamma-aminobutyric acid (GABA). This is the chemical missing in the affected motor neurons. GABA is an important (well, crucial) suppressor of nerve over-activity, hyper-excitability. When deficient, nerves fire too easily, causing all sorts of end-of-nerve anomalies.
My case of HSP is not bad enough to prompt the intense surgical procedure of implanting the rubber bladder in my spinal cord, thankfully. My case does not seem to be advancing, thankfully.
Here’s where blarcamesine will come into play with probably all forms of both HSP and PLS. In virtually all cases, neurons are lacking proper, effective concentrations of GABA; hence the over-excitability of the nerves. It was noted in the early findings of blarcamesine against Rett syndrome, in the early safety/tolerability study, that levels of GABA were dramatically increased, normalized by the drug; yielding increased normalization of motor neuron function.
Many years ago, there was a small study of blarcamesine included in the drinking water of lab rats with HSP genes. Like myself, they had reduced control and function of their spastic rear legs. Then, after they drank water with some blarcamesine in it, they rather promptly (in a week or two, as I recall) regained complete motor control of their leg muscles and twirled inside the exercise wheel like normal rats. Blarcamesine (Anavex 2-73) completely obviated the GABA deficiency, allowed normal walking. A cure, dare I say.
(Two years ago, my computer hard drive crashed; I lost the copy of that report; which I believe was in France. I’ve been unable to find it on the internet. If anyone can retrieve it, please post.)
A rare disease? Yes. “The HSP incidence rate in the United States is about 20,000 people.” But for many, very tragic, in the most severe cases:
https://sp-foundation.org/understanding-pls-hsp/hsp.html
When available, I’ll be one of the first to take blarcamesine, off-label, for my HSP. Will be rather expensive, my health insurance won’t pay for it. May have to liquidate a few AVXL shares, then.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
